107 related articles for article (PubMed ID: 28418885)
1. Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.
Slobbe P; Windhorst AD; Adamzek K; Bolijn M; Schuit RC; Heideman DAM; van Dongen GAMS; Poot AJ
Oncotarget; 2017 Jun; 8(24):38337-38350. PubMed ID: 28418885
[TBL] [Abstract][Full Text] [Related]
2. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
Wagenaar TR; Ma L; Roscoe B; Park SM; Bolon DN; Green MR
Pigment Cell Melanoma Res; 2014 Jan; 27(1):124-33. PubMed ID: 24112705
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Evaluation of [
Jiang C; Xie L; Zhang Y; Fujinaga M; Mori W; Kurihara Y; Yamasaki T; Wang F; Zhang MR
Mol Imaging; 2018; 17():1536012118795952. PubMed ID: 30251592
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
6. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA
Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
9. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM
Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib: the road to personalized medicine in melanoma.
Amaria RN; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Feb; 48(2):109-18. PubMed ID: 22384451
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
12. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
15. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
16. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
Grippo JF; Zhang W; Heinzmann D; Yang KH; Wong J; Joe AK; Munster P; Sarapa N; Daud A
Cancer Chemother Pharmacol; 2014 Jan; 73(1):103-11. PubMed ID: 24178368
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib induces senescence features in melanoma cells.
Haferkamp S; Borst A; Adam C; Becker TM; Motschenbacher S; Windhövel S; Hufnagel AL; Houben R; Meierjohann S
J Invest Dermatol; 2013 Jun; 133(6):1601-9. PubMed ID: 23321925
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
20. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]